Company profile: Cyrus
1.1 - Company Overview
Company description
- Provider of protein design software and services, including the Rosetta software combining physics-based modeling and statistical patterns to design protein binders, de novo proteins, and assemblies; the Cyrus software platform with Rosetta protocols, AI, cloud workflow automation, and in-house structure/data analysis; services for protein design, deep mutational scanning, cytokine engineering; and Next Gen IdeS enzyme for IgG-mediated disorders.
Products and services
- Cyrus Software Platform: A proprietary platform integrating Rosetta protocols, AI algorithms, cloud workflow automation, and in-house protein structure and data analysis for protein design and automated workflow execution
- Rosetta Software: A physics-based package combining statistical patterns to design proteins, including protein binders, de novo proteins, and macromolecular assemblies
- Protein Design: A custom-engineered service using advanced tools to engineer novel biologics by re-engineering existing proteins, focusing on structure prediction, immunogenicity reduction, stability, solubility, target binding affinity, and specificity.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cyrus
Cellarity
HQ: United States
Website
- Description: Provider of AI and single-cell omics–driven drug discovery solutions, including the Cellarity Platform to address cellular dysfunction across diseases; the Intervention Library to predict perturbation impacts on cell behaviors; the Cellarity Map to identify gene networks from health to disease; a drug discovery pipeline in hematology and immunology; and a MASH collaboration with Novo Nordisk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellarity company profile →
DSG
HQ: United States
Website
- Description: Provider of information technology services focused on data management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DSG company profile →
Eclipse Solutions
HQ: United States
Website
- Description: Provider of clinical technology with data management, biostatistics, consulting, and certified medical and drug coding solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eclipse Solutions company profile →
Albert Labs
HQ: Canada
Website
- Description: Provider of pharmaceutical drug development services focused on mental health, pursuing regulatory approval for active compounds. Offerings include KRN-101, a natural psilocybin medicine for cancer-related anxiety; psychedelic-assisted therapy training for mental health professionals; and real-world evidence studies to accelerate development and access of mental health medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Albert Labs company profile →
Quantitative Medicine
HQ: United States
Website
- Description: Provider of an in silico predictive modeling platform, Computational Research Engine (CoRE), for constructing, assessing, validating, and deploying highly accurate predictive models to efficiently guide testing and solve complex drug discovery optimization problems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quantitative Medicine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cyrus
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cyrus
2.2 - Growth funds investing in similar companies to Cyrus
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cyrus
4.2 - Public trading comparable groups for Cyrus
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →